Common Hepatic Lipase Gene Promoter Variant Determines Clinical Response to Intensive Lipid-Lowering Treatment
- 13 February 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 103 (6) , 792-798
- https://doi.org/10.1161/01.cir.103.6.792
Abstract
Background—The common −514 C→T polymorphism in the promoter region of the hepatic lipase (HL) gene affects HL activity. The C allele is associated with higher HL activity, more dense and atherogeni...Keywords
This publication has 18 references indexed in Scilit:
- Hepatic lipaseCurrent Opinion in Lipidology, 1999
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene. The LOCAT Study Invsestigators.Journal of Clinical Investigation, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein BNew England Journal of Medicine, 1990
- Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosisAmerican Heart Journal, 1987
- [8] Single vertical spin density gradient ultracentrifugationPublished by Elsevier ,1986
- Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2 in manAtherosclerosis, 1980